Xilio Therapeutics
30 hedge funds and large institutions have $13.4M invested in Xilio Therapeutics in 2024 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 3 increasing their positions, 6 reducing their positions, and 8 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
48% more capital invested
Capital invested by funds: $9.1M → $13.4M (+$4.34M)
1.06% less ownership
Funds ownership: 4.29% → 3.23% (-1.1%)
9% less funds holding
Funds holding: 33 → 30 (-3)
25% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 8
50% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 6
Top Buyers
| 1 |
Balyasny Asset Management
Chicago,
Illinois
|
+$233K |
| 2 |
Millennium Management
New York
|
+$27.5K |
| 3 |
Renaissance Technologies
New York
|
+$27.4K |
| 4 |
SFG
SevenBridge Financial Group
Harrisburg,
Pennsylvania
|
+$21.4K |
| 5 |
PI
PFG Investments
Woodbury,
New York
|
+$20.7K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Royal Bank of Canada
Toronto,
Ontario, Canada
| $1K | +$48 | +5 | +15% |
|
|
KFI
27
Key Financial Inc
West Chester,
Pennsylvania
| $896 | – | – | – |
|
28
UBS Group
Zurich,
Switzerland
| $217 | – | – | – |
|
29
Wells Fargo
San Francisco,
California
| $117 | – | – | – |
|
|
FIA
30
FNY Investment Advisers
New York
| $29 | +$18.9K | +1,964 | New |
|
31
Qube Research & Technologies (QRT)
London,
United Kingdom
| $4 | – | – | – |
|
|
OCA
32
Octagon Capital Advisors
New York
| – | -$982K | -127,500 | Closed |
|
|
AG
33
Artal Group
Luxembourg
| – | -$248K | -32,143 | Closed |
|
|
LCM
34
Laurion Capital Management
New York
| – | -$64.3K | -8,346 | Closed |
|
|
ACH
35
ArrowMark Colorado Holdings
Denver,
Colorado
| – | -$45.9K | -5,955 | Closed |
|
36
Citadel Advisors
Miami,
Florida
| – | -$28.3K | -3,673 | Closed |
|
|
VF
37
Virtu Financial
New York
| – | -$6K | -769 | Closed |
|
|
CFB
38
Cullen/Frost Bankers
San Antonio,
Texas
| – | -$55 | -7 | Closed |
|
39
Bank of America
Charlotte,
North Carolina
| – | -$6 | -1 | Closed |
|
XLO Hedge Fund Activity: Q1 2024 in Review
30 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Xilio Therapeutics (XLO) for Q1 2024, worth a combined $13.4M — up 48% from $9.1M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of XLO and 6 opened new positions — a net loss of 2 holders — while 6 trimmed existing stakes and 3 added.
The largest buyer was Balyasny Asset Management, opening a new position worth an estimated $233K. The largest seller was Atlas Venture Life Science Advisors, cutting an estimated $1.22M.
- 30 institutional investors held Xilio Therapeutics (XLO) as of Q1 2024, down from 33 in Q4 2023.
- Funds reported $13.4M of Xilio Therapeutics stock for Q1 2024, up 48% quarter-over-quarter.
- 6 funds opened new Xilio Therapeutics positions in Q1 2024 and 8 closed out, a net change of -2 holders.
- The largest Xilio Therapeutics buyer in Q1 2024 was Balyasny Asset Management, an estimated $233K added.
- The largest Xilio Therapeutics seller in Q1 2024 was Atlas Venture Life Science Advisors, an estimated $1.22M sold.
Based on aggregated 13F filings for Q1 2024.